Generalized phase I‐II designs to increase long term therapeutic success rate
Pharmaceutical Statistics · 2023-07 · 22 (4) · 692-706
DOI: 10.1002/pst.2301 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pharmaceutical Statistics, online erschienen am 11.04.2023. Verfasst von Peter F Thall und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, M.D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Research Design, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Designs for early phase dose finding clinical trials typically are either phase I based on toxicity, or phase I‐II based on toxicity and efficacy. These designs rely on the implicit assumption that the dose of an experimental agent chosen using these short‐term outcomes will maximize the agent's long‐term therapeutic success rate. In many clinical settings, this assumption is not true. A dose selected in an early phase oncology trial may give suboptimal progression‐free survival or overall survival time, often due to a high rate of relapse following response. To address this problem, a new family of Bayesian generalized phase I‐II designs is proposed. First, a conventional phase I‐II design based on short‐term outcomes is used to identify a set of candidate doses, rather than selecting one dose. Additional patients then are randomized among the candidates, patients are followed for a predefined longer time period, and a final dose is selected to maximize the long‐term therapeutic success rate, defined in terms of duration of response. Dose‐specific sample sizes in the randomization are determined adaptively to obtain a desired level of selection reliability. The design was motivated by a phase I‐II trial to find an optimal dose of natural killer cells as targeted immunotherapy for recurrent or treatment‐resistant B‐cell hematologic malignancies. A simulation study shows that, under a range of scenarios in the context of this trial, the proposed design has much better performance than two conventional phase I‐II designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics, M.D. Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics and Health Data Science, Center for Computational Biology and Bioinformatics, Indiana University, Indianapolis, Indiana, USA.
ORCID-Profile: Peter F Thall, Yong Zang, Ying Yuan
Förderung
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
- Ralph W. and Grace M. Showalter Research Trust Fund
Zitieren
APA
Thall, P. F., Zang, Y., & Yuan, Y. (2023). Generalized phase I‐II designs to increase long term therapeutic success rate. Pharmaceutical Statistics, 22(4), 692-706. https://doi.org/10.1002/pst.2301
Vancouver
Thall PF, Zang Y, Yuan Y. Generalized phase I‐II designs to increase long term therapeutic success rate. Pharmaceutical Statistics. 2023;22(4):692-706. doi:10.1002/pst.2301
BibTeX
@article{Thall2023,
author = {Thall, Peter F and Zang, Yong and Yuan, Ying},
title = {Generalized phase I‐II designs to increase long term therapeutic success rate},
journal = {Pharmaceutical Statistics},
year = {2023},
volume = {22},
number = {4},
pages = {692--706},
doi = {10.1002/pst.2301}
}
EUVIMED